Annual Drug Patent Expirations for UPTRAVI
Uptravi is a drug marketed by Actelion and is included in two NDAs. It is available from one supplier. There are six patents protecting this drug.
Drug patent litigation for UPTRAVI.
This drug has one hundred and eighteen patent family members in thirty-seven countries.
The generic ingredient in UPTRAVI is selexipag. One supplier is listed for this compound. Additional details are available on the selexipag profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com